Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a global public health problem as it is the third most prevalent and the second most lethal cancer worldwide. Major efforts are underway to understand its molecular pathways as well as to define the tumour-associated antigens (TAAs) and tumour-specific antigens (TSAs) or neoantigens, in order to develop an effective treatment. Cell therapies are currently gaining importance, and more specifically chimeric antigen receptor (CAR)-T cell therapy, in which genetically modified T cells are redirected against the tumour antigen of interest. This immunotherapy has emerged as one of the most promising advances in cancer treatment, having successfully demonstrated its efficacy in haematological malignancies. However, in solid tumours, such as colon cancer, it is proving difficult to achieve the same results due to the shortage of TSAs, on-target off-tumour effects, low CAR-T cell infiltration and the immunosuppressive microenvironment. To address these challenges in CRC, new approaches are proposed, including combined therapies, the regional administration of CAR-T cells and more complex CAR structures, among others. This review comprehensively summarises the current landscape of CAR-T cell therapy in CRC from the potential tumour targets to the preclinical studies and clinical trials, as well as the limitations and future perspectives of this novel antitumour strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 13×
“Fourth-generation CARs or TRUCKs usually combine a second-generation CAR construct with the constitutive or inducible expression of chemokines.”
BackgroundInfluentialTop 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
NKG2D Receptor and Its Ligands in Host Defense
Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599 · cited 2×
“These ligands are expressed in response to external signals such as stress or pathogens and during neoplastic cell transformation but they are rarely present in healthy tissue [49,50].”
BackgroundZhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578 · cited 6×
“In the thi d generation, CAR eceptors contain two co-s imulatory domains in order to increase the cytokine pro uction and antitumour effect [31].”
BackgroundMethodInfluentialCD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440169 · Cited by 338
Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0362 · Cited by 143 · cited 6×
“In the early stages of tumour initiation, loss of the GUCY2C-binding ligands (guanylin or uroguanylin) occurs, resulting in silencing of the signalling pathway and promoting intestinal transformation [46,48].”
BackgroundInfluentialZhang, B.-L., Li, D., Gong, Y.-L., Huang, Y., Qin, D.-Y., Jiang, L., Liang, X., Yang, X., Gou, H.-F., Wang, Y.-S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.229 · Cited by 88
Research works printed but not linked: 95
- Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
- Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660 · DOI · Paper page
- Pareja, 2018, Inmunología del cáncer I: Bases moleculares y celulares de la respuesta inmune antitumoral, Horiz. Médico, 18, 80, 10.24265/horizmed.2018.v18n3.11 · DOI
- 2020, A brief history of CAR-T cells: From laboratory to the bedside, Acta Haematol. Pol., 51, 2, 10.2478/ahp-2020-0002 · DOI
- Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Bakkach, 2021, Colorectal cancer: From genetic landscape to targeted therapy, J. Oncol., 2021, 9918116
- Gallego, 2019, SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018), Clin. Transl. Oncol., 21, 46, 10.1007/s12094-018-02002-w · DOI
- Prashanth, 2019, Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors, Prz. Gastroenterol., 14, 89
- Meyerhardt, 2005, Drug Therapy: Systemic therapy for colorectal cancer, Arch. Oncol., 352, 476
- Wolpin, 2008, Systemic treatment of colorectal cancer, Gastroenterology, 134, 1296, 10.1053/j.gastro.2008.02.098 · DOI · Paper page
- Arruebo, 2011, Assessment of the evolution of cancer treatment therapies, Cancers, 3, 3279, 10.3390/cancers3033279 · DOI · Paper page
- Carluccio, 2015, Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer, J. Cell. Physiol., 230, 1457, 10.1002/jcp.24886 · DOI
- Ishikawa, 2018, Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer, Int. J. Cancer, 142, 2599, 10.1002/ijc.31285 · DOI
- Xing, 2019, Enhanced antitumor effect of cytotoxic T lymphocytes induced by dendritic cells pulsed with colorectal cancer cell lysate expressing α-gal epitopes, Oncol. Lett., 18, 864
- Pan, 2014, The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer, Tumor Biol., 35, 701, 10.1007/s13277-013-1096-1 · DOI
- Pan, Q.Z., Zhao, J.J., Yang, C.P., Zhou, Y.Q., Lin, J.Z., Tang, Y., Gu, J.M., Wang, Q.J., Li, Y.Q., and He, J. (2020). Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection. Oncoimmunology, 9. · DOI
- Zhang, 2014, Effects of cytokine-induced killer cell treatment in colorectal cancer patients: A retrospective study, Biomed. Pharmacother., 68, 715, 10.1016/j.biopha.2014.07.010 · DOI
- Zhao, 2016, Autologous Cytokine-Induced Killer Cells improves overall survival of metastatic colorectal cancer patients: Results from a phase II clinical trial, Clin. Colorectal Cancer, 15, 228, 10.1016/j.clcc.2016.02.005 · DOI
- Xie, 2017, Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment, World J. Surg. Oncol., 15, 4, 10.1186/s12957-017-1278-1 · DOI
- Zhu, 2014, Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy, Biomed Res. Int., 2014, 5, 10.1155/2014/603871 · DOI · Paper page
- Gao, 2014, Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients, PLoS ONE, 9, 1
- Ishii, 2006, Dendritic cell therapy with interferon-α synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model, Gene Ther., 13, 78, 10.1038/sj.gt.3302608 · DOI
- Veluchamy, 2016, Combination of NK cells and cetuximab to enhance anti-tumor responses in RAS mutant metastatic colorectal cancer, PLoS ONE, 11, 1, 10.1371/journal.pone.0157830 · DOI · Paper page
- Chen, 2016, Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model, Oncol. Lett., 12, 1868, 10.3892/ol.2016.4835 · DOI
- Li, 2018, Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma, Cytotherapy, 20, 134, 10.1016/j.jcyt.2017.09.009 · DOI
- Yoshida, 2016, Adoptive chemoimmunotherapy using activated αβ T cells for stage IV colorectal cancer, Anticancer Res., 36, 3741
- Parkhust, 2009, Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells, Clin. Cancer Res., 15, 169, 10.1158/1078-0432.CCR-08-1638 · DOI · Paper page
- Breman, 2018, Overcoming target driven fratricide for T cell therapy, Front. Immunol., 9, 2940, 10.3389/fimmu.2018.02940 · DOI
- Guedan, 2019, Engineering and design of chimeric antigen receptors, Mol. Ther.-Methods Clin. Dev., 12, 145, 10.1016/j.omtm.2018.12.009 · DOI · Paper page
- Chmielewski, 2015, TRUCKs: The fourth generation of CARs, Expert Opin. Biol. Ther., 15, 1145, 10.1517/14712598.2015.1046430 · DOI · Paper page
- D’Aloia, M.M., Zizzari, I.G., Sacchetti, B., Pierelli, L., and Alimandi, M. (2018). CAR-T cells: The long and winding road to solid tumors. Cell Death Dis., 9. · DOI · Paper page
- Trapani, 2017, Immunotherapy of cancer, Aust. Fam. Physician, 46, 194
- Wagner, 2018, Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens, World J. Gastroenterol., 24, 5418, 10.3748/wjg.v24.i48.5418 · DOI · Paper page
- Feng, 2021, T-cell-based immunotherapy in colorectal cancer, Cancer Lett., 498, 201, 10.1016/j.canlet.2020.10.040 · DOI · Paper page
- Bakarurraini, N.A.A.R., Mutalib, N.S.A., Jamal, R., and Abu, N. (2020). The landscape of tumor-specific antigens in colorectal cancer. Vaccines, 8. · DOI
- Han, 2020, The old CEACAMs find their new role in tumor immunotherapy, Invest. New Drugs, 38, 1888, 10.1007/s10637-020-00955-w · DOI
- Zhang, 2017, Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers, Mol. Ther., 25, 1248, 10.1016/j.ymthe.2017.03.010 · DOI · Paper page
- Jelski, 2020, Biochemical markers of colorectal cancer–present and future, Cancer Manag. Res., 12, 4789, 10.2147/CMAR.S253369 · DOI
- Lisby, 2021, GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer, Expert Rev. Precis. Med. Drug Dev., 6, 117, 10.1080/23808993.2021.1876518 · DOI
- Magee, 2016, GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity, Oncoimmunology, 5, e1227897, 10.1080/2162402X.2016.1227897 · DOI
- Zingoni, A., Molfetta, R., Fionda, C., Soriani, A., Paolini, R., Cippitelli, M., Cerboni, C., and Santoni, A. (2018). NKG2D and its ligands: “One for all, all for one”. Front. Immunol., 9. · DOI · Paper page
- Dhar, 2018, NKG2D and its ligands in cancer, Curr. Opin. Immunol., 51, 55, 10.1016/j.coi.2018.02.004 · DOI · Paper page
- Sabbah, 2020, Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors, Curr. Top. Med. Chem., 20, 815, 10.2174/1568026620666200303123102 · DOI · Paper page
- Sigismund, 2018, Emerging functions of the EGFR in cancer, Mol. Oncol., 12, 3, 10.1002/1878-0261.12155 · DOI · Paper page
- Huang, 2018, MiR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy, J. Hematol. Oncol., 11, 1
- Siena, 2018, Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer, Ann. Oncol., 29, 1108, 10.1093/annonc/mdy100 · DOI · Paper page
- Styczen, 2015, HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer, Oncotarget, 6, 15065, 10.18632/oncotarget.3527 · DOI · Paper page
- Liang, 2018, Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells, Cancer Lett., 433, 165, 10.1016/j.canlet.2018.06.040 · DOI
- Eyvazi, 2018, Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update, Curr. Cancer Drug Targets, 18, 857, 10.2174/1568009618666180102102311 · DOI
- Gires, 2020, Expression and function of epithelial cell adhesion molecule EpCAM: Where are we after 40 years?, Cancer Metastasis Rev., 39, 969, 10.1007/s10555-020-09898-3 · DOI · Paper page
- Cho, 2019, The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma, Pathol. Res. Pract., 215, 171, 10.1016/j.prp.2018.10.024 · DOI
- Klampatsa, 2021, Mesothelin-targeted CAR-T cell therapy for solid tumors, Expert Opin. Biol. Ther., 21, 473, 10.1080/14712598.2021.1843628 · DOI
- Inoue, 2020, Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer, Oncol. Lett., 19, 1741
- Nabavinia, 2017, Anti-MUC1 aptamer: A potential opportunity for cancer treatment, Med. Res. Rev., 37, 1518, 10.1002/med.21462 · DOI · Paper page
- Li, 2020, PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells, J. Chem. Inf. Model., 25, 1765
- Reiswich, V., Gorbokon, N., Luebke, A.M., Burandt, E., Menz, A., Kluth, M., Hube-Magg, C., Wittmer, C., Weidemann, S., and Fraune, C. (2021). Pattern of placental alkaline phosphatase (PLAP) expression in human tumors: A tissue microarray study on 12,381 tumors. J. Pathol. Clin. Res. · DOI
- Akbari, 2020, CD133: An emerging prognostic factor and therapeutic target in colorectal cancer, Cell Biol. Int., 44, 368, 10.1002/cbin.11243 · DOI · Paper page
- Abbasian, 2019, The most reliable surface marker for the identification of colorectal cancer stem-like cells: A systematic review and meta-analysis, J. Cell. Physiol., 234, 8192, 10.1002/jcp.27619 · DOI · Paper page
- Lee, 2018, c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival, Clin. Colorectal Cancer, 17, 165, 10.1016/j.clcc.2018.02.013 · DOI
- Safaie Qamsari, E., Safaei Ghaderi, S., Zarei, B., Dorostkar, R., Bagheri, S., Jadidi-Niaragh, F., Somi, M.H., and Yousefi, M. (2017). The c-Met receptor: Implication for targeted therapies in colorectal cancer. Tumour Biol., 39. · DOI
- Rahbar, 2018, PSMA Theranostics: Current Status and Future Directions, Mol. Imaging, 17, 1, 10.1177/1536012118776068 · DOI · Paper page
- Cuda, 2020, PET imaging quantifying 68Ga-PSMA-11 uptake in metastatic colorectal cancer, J. Nucl. Med., 61, 1576, 10.2967/jnumed.119.233312 · DOI
- Ang, 2017, Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis, Oncotarget, 8, 13545, 10.18632/oncotarget.14592 · DOI · Paper page
- Chi, 2019, Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12, Cancer Med., 8, 4753, 10.1002/cam4.2361 · DOI · Paper page
- Deng, 2019, Antitumor activity of NKG2D CAR-T cell against human colorectal cancer cells in vitro and in vivo, Am. J. Cancer Res., 9, 945
- Ramos, 2018, In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas, Mol. Ther., 26, 2727, 10.1016/j.ymthe.2018.09.009 · DOI · Paper page
- Hombach, 2019, Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− Tumors, Mol. Ther., 27, 1825, 10.1016/j.ymthe.2019.06.007 · DOI · Paper page
- Teng, 2019, Chimeric antigen receptor-modified T cells repressed solid tumors and their relapse in an established patient-derived colon carcinoma xenograft model, J. Immunother., 42, 33, 10.1097/CJI.0000000000000251 · DOI · Paper page
- Hombach, A.A., Geumann, U., Günther, C., Hermann, F.G., and Abken, H. (2020). IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells. Cells, 9. · DOI · Paper page
- Sureban, S.M., Berahovich, R., Zhou, H., Xu, S., Wu, L., Ding, K., May, R., Qu, D., Bannerman-menson, E., and Golubovskaya, V. (2020). DCLK1 Monoclonal Antibody-Based CAR-T Cells Asa Novel Treatment Strategy against Human Colorectal Cancers. Cancers, 12. · DOI
- Katz, 2016, Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery, Cancer Gene Ther., 23, 142, 10.1038/cgt.2016.14 · DOI · Paper page
- Zhang, 2021, The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice, Mol. Ther. Oncolytics, 20, 556, 10.1016/j.omto.2021.02.013 · DOI
- Mullins, 2020, Mouse models of colorectal cancer: Past, present and future perspectives, World J. Gastroenterol., 26, 1394, 10.3748/wjg.v26.i13.1394 · DOI · Paper page
- Feng, 2017, Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma, J. Hematol. Oncol., 10, 1, 10.1186/s13045-016-0378-7 · DOI · Paper page
- Zhou, 2019, Construction of chimeric antigen receptor-modified T cells targeting EpCAM and assessment of their anti-tumor effect on cancer cells, Mol. Med. Rep., 20, 2355
- Ang, 2020, Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts, Mol. Ther. Oncolytics, 17, 421, 10.1016/j.omto.2020.04.013 · DOI
- Goff, 2019, Pilot trial of adoptive transfer of chimeric antigen receptor-Transduced T cells targeting EGFRvIII in patients with glioblastoma, J. Immunother., 42, 126, 10.1097/CJI.0000000000000260 · DOI · Paper page
- Sampson, 2014, EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss, Clin. Cancer Res., 20, 972, 10.1158/1078-0432.CCR-13-0709 · DOI · Paper page
- Katz, 2020, HITM-SIR: Phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases, Cancer Gene Ther., 27, 341, 10.1038/s41417-019-0104-z · DOI
- Katz, 2020, HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery, J. Immunother. Cancer, 8, 1, 10.1136/jitc-2020-001097 · DOI
- Lichtenstern, C.R., Ngu, R.K., Shalapour, S., and Karin, M. (2020). Immunotherapy, Inflammation and Colorectal Cancer. Cells, 9. · DOI · Paper page
- Morgan, 2020, Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells, Front. Immunol., 11, 1965, 10.3389/fimmu.2020.01965 · DOI
- Sallman, 2018, Abstract CT129: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia, Cancer Res., 78, CT129, 10.1158/1538-7445.AM2018-CT129 · doi:10.1158/1538-7445.am2018-ct129
- Depil, 2020, ‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges, Nat. Rev. Drug Discov., 19, 185, 10.1038/s41573-019-0051-2 · DOI · Paper page
- Yazdanifar, M., Barbarito, G., Bertaina, A., and Airoldi, I. (2020). γδ T Cells: The Ideal Tool for Cancer Immunotherapy. Cells, 9. · DOI
- Prenen, 2021, Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC, J. Clin. Oncol., 39, 74, 10.1200/JCO.2021.39.3_suppl.74 · doi:10.1200/jco.2021.39.3_suppl.74
- Dai, 2020, Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: A single-arm, open-label, phase II trial, Oncoimmunology, 9, 1, 10.1080/2162402X.2020.1846926 · DOI · Paper page
- Lonez, 2018, Van Den Canon, J.-L.; Carrasco, J.; Verma, B.; et al. Abstract CT123: A phase I study assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases, Cancer Res., 78, CT123, 10.1158/1538-7445.AM2018-CT123 · doi:10.1158/1538-7445.am2018-ct123
- Braun, 2018, Abstract CT134: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of a NKG2D-based CAR-T therapy CYAD-01, in patients with unresectable liver metastases from colorectal cancer, Cancer Res., 78, CT134, 10.1158/1538-7445.AM2018-CT134 · doi:10.1158/1538-7445.am2018-ct134
- Sur, D., Havasi, A., Cainap, C., Samasca, G., Burz, C., Balacescu, O., Lupan, I., Deleanu, D., and Irimie, A. (2020). Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J. Clin. Med., 9. · DOI
- Zhang, 2019, Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies, Cancer Lett., 458, 123, 10.1016/j.canlet.2019.05.017 · DOI
- Bollard, 2002, Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity, Blood, 99, 3179, 10.1182/blood.V99.9.3179 · DOI · Paper page
- Kono, 1996, Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity, Eur. J. Immunol., 26, 1308, 10.1002/eji.1830260620 · DOI · Paper page
- Leen, 2014, Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor, Mol. Ther., 22, 1211, 10.1038/mt.2014.47 · DOI · Paper page
- Dillard, 2020, Colorectal cysts as a validating tool for CAR therapy, BMC Biotechnol., 20, 1, 10.1186/s12896-020-00623-0 · DOI
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“This includes BiTEs and oncolytic viruses (discussed above), antitumor vaccines, and different types of adoptive cell transfer, such as chimeric antigen receptor (CAR) T cell therapy, tumor-infiltrating lymphocyte therapy, and T cell receptor therapy [37,38,226].”
Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40
“This type of therapy has seen the most success against hematological malignancies in the United States [83].”
BackgroundColorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
Cell Therapy as Target Therapy against Colon Cancer Stem Cells
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
Metadata
- Authors
- Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González-Vallinas, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-10-29
- Volume
- 22
- Issue
- 21
- Pages
- 11781
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3209309812
- Cited by
- 86
- References
- 11
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. https://app.cochat.ai/papers/10.3390/ijms222111781
- The paper
- Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González-Vallinas, M. (2021). Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222111781
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.